QUALITY OF LIFE OF PATIENTS SUFFERING FROM SCHIZOPHRENIA AND TREATED WITH LONG-ACTING RISPERIDONE AND PALIPERIDONE-PALMITATE
Abstract
Introduction: In recent decades, researchers devoted a lot of attention to studying the quality of life of people with mental disorders. Improving quality of life of people with schizophrenia is becoming an obligation of pharmacological therapy.
The aim: The aim of the paper was to assess certain aspects of quality of life of the patients suffering from schizophrenia treated with long-acting risperidone and paliperidonе-palmitate and to determine the impact of socio-demographic characteristics on the quality of life of these patients.
Method: The study was done as a cross-sectional investigation after receiving the decision of the Ethics Committee, and it was conducted according to the principles of Good Clinical Practice. The study covered 45 patients of both sex with the diagnosis of schizophrenia (MKB-10, F20.0-F20.9). The respondents were classified in two groups of 25 and 20 patients: those who received long-acting risperidone and those who received long-acting paliperidone palmitate, respectively. The assessment of the quality of life of respondents was done by a scale of personal and social impact (PSP). The socio-demographic questionnaire was used to assess the influence of socio-demographic characteristics on health-related quality of life.
Results: Statistically significant differences were observed in personal and social functioning, in favor of patients treated with long-acting paliperidone palmitate (PSP score: 78.30 ± 5.03). The subjects of this group were more satisfied with their own health and themselves than those who were treated by long-acting risperidone. Data obtained by analyzing sociodemographic questionnaires indicate that patients who received long-acting risperidone had more hospitalizations annually (r = 0.03) compared to patients treated by the paliperidone-palmitate. There was also a statistically significant increase in absenteeism (r = 0.009) from work in patients receiving long-acting risperidone.
Conclusion: Our study showed higher scores of personal and social functioning in the group of patients treated with long-acting paliperidone-palmitate. Longer dosing interval of paliperidone-palmitate enables greater mobility of the patients within the society and diminished sense of stigmatization.
References
Shaun M. Eack, Christina E. Newhill. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007; 33(5):1225-37.
Lauer G. Ergebnisse der lebensqualitatsforcshung bei chronich psychisch kranken. Psychiatr Prax 1993. 20: 80-90.
Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am J Psychiatry. 1997; 154(1): 99-105.
Solanki RK, Singh P, Midha A, Chugh K. Schizophre-nia: impact on quality of life. Indian J Psychiatry (serial online). 2008; 50: 181-6.
Miljković S, Vukić D, Trajanović Lj. Quality of Life in Mental Disorders. Niš: The Society of Behavioral Theory and Practice; 2004.
Chrisholm D. Bhugra D. Sociocultural and oeconomic aspects of quality of life measurement. Eur Psychiatry 1997. 12: 2015.
Мирослава Ј. Маја И. Александар Д. Владимир П. Нове могућности у терапији схизофрених пације-ната: дугоделујући рисперидон (Rispolept Consta). Енграми. вол. 26. 2004. бр. 1-2.
Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995; 10(Suppl 3):133-8.
Chue P. et al. Efficacy and safety of long-acting risperi-done microspheres and risperidone oral tablets. Schizophrenia Research 2002; 53 (Suppl. 3): 174-5.
Агеницја за лекове и медицинска средства Републи-ке Србије. Xeplion® 25mg-150mg/0,25ml-1,5ml. Доступно на: https://www.alims.gov.rs/ciril/files/lekovi/pil/515-01-5465-11-001.pdf Последњи пут виђено: 03. 04. 2018.
Salokangas RK, Honkonen T, Stengard E, Koivisto AM. To be or not to be married – that is the question of quality of life in men with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2001; 30(8): 381-90.
Becker T, Leese M, Clarkson P, Taylor RE, Turner D, Kleckham J, et al. Links between social network and quality of life: an epidemiologically representative study of psychotic patients in South London. Soc Psychiatry Psychiatr Epidemiol. 1998; 33(7): 229-304.
Bengtsson-Tops A, Hansson L. Quantitative and qualitative aspects of the social network in schizophrenic patients living in the community. Relationship to sociodemographic characteristics and clinical factors and subjective quality of life. Int J Soc Psychiatry. 2001; 47(3): 67-77.
Chan SW, Hsiung PC, Thompson DR, Chen SC, Hwu HG. Healthrelated quality of life of Chinese people with schizophrenia in Hong Kong and Taipei: a cross-sectional analysis. Res Nurs Health. 2007; 30(3): 261-9.
Salokangas RK, Honkonen T, Stengard E, Koivisto AM. Subjective life satisfaction and living situations of persons in Finland with long-term schizophrenia. Psychiatr Serv. 2006; 57(3): 373-81.
Kugo A, Terada S, Isbizu H, Takeda T, Sato S, Habara T, et al. Quality of life for patients with schizophrenia in a Japanese psychiatric hospital. Psychiatry Res. 2006; 144(1): 49-56.
Ritsner M, Modai I, Endicott J, Rivkin O, Nechamkin Y, Barak P, et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry. 2000; 61:880-9.
Potkin SG, Loze JY, Forray C, et all. Multidimensional аssessment of functional оutcomes in schizophrenia: results from qualify, a head to head trial of aripiprazole once monthly and aliperidone-palmitate. 2017. 1;20(1): 40-9.